GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Cyclically Adjusted Price-to-FCF

Agenus (FRA:AJ8) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Agenus's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Cyclically Adjusted Price-to-FCF Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agenus's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Agenus's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted Price-to-FCF falls into.



Agenus Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Agenus's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Agenus's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-34.546/131.7762*131.7762
=-34.546

Current CPI (Mar. 2024) = 131.7762.

Agenus Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -2.374 100.560 -3.111
201409 -2.084 100.428 -2.735
201412 -3.153 99.070 -4.194
201503 0.824 99.621 1.090
201506 -3.282 100.684 -4.296
201509 -4.068 100.392 -5.340
201512 -4.397 99.792 -5.806
201603 -4.780 100.470 -6.269
201606 -4.118 101.688 -5.336
201609 -5.895 101.861 -7.626
201612 -4.434 101.863 -5.736
201703 -3.050 102.862 -3.907
201706 -5.091 103.349 -6.491
201709 -4.553 104.136 -5.761
201712 -4.455 104.011 -5.644
201803 -6.601 105.290 -8.262
201806 -5.083 106.317 -6.300
201809 -3.775 106.507 -4.671
201812 -5.322 105.998 -6.616
201903 8.944 107.251 10.989
201906 -4.859 108.070 -5.925
201909 -3.777 108.329 -4.594
201912 -4.287 108.420 -5.211
202003 -4.386 108.902 -5.307
202006 -4.042 108.767 -4.897
202009 -3.021 109.815 -3.625
202012 -3.103 109.897 -3.721
202103 -3.601 111.754 -4.246
202106 -4.307 114.631 -4.951
202109 7.510 115.734 8.551
202112 -2.199 117.630 -2.463
202203 -4.003 121.301 -4.349
202206 -4.228 125.017 -4.457
202209 -3.374 125.227 -3.550
202212 -3.825 125.222 -4.025
202303 -71.101 127.348 -73.573
202306 -3.388 128.729 -3.468
202309 -3.404 129.860 -3.454
202312 -1.940 129.419 -1.975
202403 -34.546 131.776 -34.546

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agenus  (FRA:AJ8) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Agenus Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Agenus's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (FRA:AJ8) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines